Cardiovascular Sales & Earnings Roundup: Medtronic TAVR Disappoints While Abbott And Boston Scientific See Structural Success In 2019
Executive Summary
The top five cardiovascular device companies, as ranked by Medtech Insight’s MTI 100, have reported their sales and earnings for the last quarter of the calendar year 2019. Here are the highlights from the most recent presentations from Medtronic, Abbott Laboratories, Boston Scientific, Edwards Lifesciences and Terumo.
You may also be interested in...
Edwards Sees ‘Tough Time’ Ahead For TAVR Patients
The COVID-19 pandemic is severely hindering patient access to transcatheter aortic valve replacement procedures. Edwards Lifesciences, the market leader, is hopeful that TAVR volumes will recover by the end of 2020, but that will be too late for many patients.
Abbott Receives CE Mark For FlexNav TAVR System
Abbott enters the highly competitive TAVR market with its newly CE-marked FlexNav delivery system for Portico.
Boston Scientific Expects Up To $40M Impact In Q1 From Coronavirus Outbreak; 10%-12% Revenue Increase For 2020
Boston Scientific said in an earnings call it expects the coronavirus outbreak may lead to a $10m to $40m loss in first-quarter sales as a result of lower procedures volumes and disrupted supply chains in China. For the fourth quarter, Boston Scientific reported $2.9bn in sales.